MP Group: Outlook on the CROs for the new-age Biopharma
It is our pleasure to share with you our outlook on the ‘CROs for the new-age Biopharma’. The drug development landscape is rapidly shifting towards complex targets and new drug modalities, with growth in cell & gene therapy and ADC pipeline now outpacing traditional small molecule drug candidates. As a result, the Biopharma cos are seeking CROs that can become an extension of their scientific think-tank, providing intellectual inputs and cutting edge research insights. It will be critical for CROs…